Advertisement


Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Advertisement